Ali Tabarroki

1.0k total citations
27 papers, 679 citations indexed

About

Ali Tabarroki is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Ali Tabarroki has authored 27 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 16 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Ali Tabarroki's work include Acute Myeloid Leukemia Research (18 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers) and Eosinophilic Disorders and Syndromes (5 papers). Ali Tabarroki is often cited by papers focused on Acute Myeloid Leukemia Research (18 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers) and Eosinophilic Disorders and Syndromes (5 papers). Ali Tabarroki collaborates with scholars based in United States, Brazil and Iran. Ali Tabarroki's co-authors include Ramón V. Tiu, Valeria Visconte, Mikkael A. Sekeres, Yogen Saunthararajah, Ania Jankowska, Edy Hasrouni, Hideki Makishima, Anjali S. Advani, Sara Teresinha Olalla Saad and Fabı́ola Traina and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ali Tabarroki

24 papers receiving 674 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ali Tabarroki United States 10 448 348 225 71 61 27 679
Estelle Verburgh South Africa 10 447 1.0× 437 1.3× 227 1.0× 52 0.7× 40 0.7× 35 824
Naoko Hosono Japan 14 341 0.8× 317 0.9× 129 0.6× 111 1.6× 37 0.6× 60 646
Michele Cedrone Italy 16 375 0.8× 296 0.9× 237 1.1× 81 1.1× 24 0.4× 36 620
Vilasini Shetty United States 15 654 1.5× 328 0.9× 189 0.8× 162 2.3× 29 0.5× 21 811
A. Kuendgen Germany 10 572 1.3× 232 0.7× 296 1.3× 30 0.4× 35 0.6× 22 690
Silvana Capalbo Italy 15 289 0.6× 144 0.4× 271 1.2× 179 2.5× 41 0.7× 37 669
Ryan J. Mattison United States 12 273 0.6× 238 0.7× 159 0.7× 30 0.4× 31 0.5× 58 518
Arjan van de Loosdrecht Netherlands 9 547 1.2× 123 0.4× 252 1.1× 105 1.5× 16 0.3× 22 643
Saman Abbas Netherlands 8 619 1.4× 676 1.9× 234 1.0× 46 0.6× 56 0.9× 10 1.1k
Kathrin Nachtkamp Germany 15 808 1.8× 184 0.5× 427 1.9× 52 0.7× 44 0.7× 53 876

Countries citing papers authored by Ali Tabarroki

Since Specialization
Citations

This map shows the geographic impact of Ali Tabarroki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Tabarroki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Tabarroki more than expected).

Fields of papers citing papers by Ali Tabarroki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Tabarroki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Tabarroki. The network helps show where Ali Tabarroki may publish in the future.

Co-authorship network of co-authors of Ali Tabarroki

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Tabarroki. A scholar is included among the top collaborators of Ali Tabarroki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Tabarroki. Ali Tabarroki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ai, Jing, Valeria Visconte, Ali Tabarroki, et al.. (2015). Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia. 15(8). 489–495. 1 indexed citations
2.
Ai, Jing, Valeria Visconte, Ali Tabarroki, et al.. (2014). Impact of Non-JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib. Blood. 124(21). 3194–3194.
3.
Visconte, Valeria, Reda Z. Mahfouz, Ali Tabarroki, et al.. (2014). Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia. 29(1). 188–195. 48 indexed citations
4.
Campos, Paula de Melo, João Agostinho Machado‐Neto, Renata Scopim‐Ribeiro, et al.. (2014). Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research. 38(10). 1245–1251. 35 indexed citations
5.
Tabarroki, Ali, Daniel J. Lindner, Valeria Visconte, et al.. (2014). Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 28(7). 1486–1493. 47 indexed citations
6.
Visconte, Valeria, Ali Tabarroki, Li Zhang, et al.. (2014). Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. Journal of Hematology & Oncology. 7(1). 89–89. 17 indexed citations
7.
Tabarroki, Ali, Rokana Taftaf, Valeria Visconte, et al.. (2014). Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib. Blood. 124(21). 1835–1835. 2 indexed citations
8.
Tabarroki, Ali & Ramón V. Tiu. (2014). Molecular Genetics of Myelofibrosis and its associated Disease Phenotypes. PubMed. 8. 53–64. 6 indexed citations
9.
Mahfouz, Reda Z., Ania Jankowska, Quteba Ebrahem, et al.. (2013). Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy. Clinical Cancer Research. 19(4). 938–948. 105 indexed citations
10.
Traina, Fabı́ola, Valeria Visconte, Paul Elson, et al.. (2013). Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 28(1). 78–87. 219 indexed citations
11.
Hamilton, Betty K., Ali Tabarroki, Paul Elson, et al.. (2013). Impact of allogeneic hematopoietic stem cell transplant (HSCT) on patients harboring the spliceosome mutation SRSF2.. Journal of Clinical Oncology. 31(15_suppl). 7008–7008. 4 indexed citations
12.
Hasrouni, Edy, Heesun J. Rogers, Ali Tabarroki, et al.. (2013). A case of mistaken identity: When lupus masquerades as primary myelofibrosis. SHILAP Revista de lepidopterología. 1. 2050313X13498709–2050313X13498709. 3 indexed citations
13.
Tabarroki, Ali, Valeria Visconte, Heesun J. Rogers, et al.. (2013). Spliceosome Gene Mutations Are Frequently Found In JAK2 Negative Myelofibrosis and Associated With Worse Clinical Outcomes. Blood. 122(21). 4063–4063. 1 indexed citations
14.
Tabarroki, Ali, Daniel J. Lindner, Valeria Visconte, et al.. (2013). Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis. Blood. 122(21). 1586–1586. 5 indexed citations
15.
Tabarroki, Ali & Ramón V. Tiu. (2012). Immunomodulatory agents in myelofibrosis. Expert Opinion on Investigational Drugs. 21(8). 1141–1154. 9 indexed citations
16.
Sekeres, Mikkael A., Ramón V. Tiu, Rami S. Komrokji, et al.. (2012). Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 120(25). 4945–4951. 98 indexed citations
17.
Liu, Yang, Ali Tabarroki, Valeria Visconte, et al.. (2012). A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN. Blood. 120(21). 1701–1701. 3 indexed citations
18.
19.
Otukesh, Hasan, et al.. (2008). Short-term and long-term outcome of hemolytic uremic syndrome in Iranian children. Journal of Nephrology. 21(5). 694–703. 11 indexed citations
20.
Otukesh, Hasan, Rozita Hoseini, Nakysa Hooman, et al.. (2006). Prognosis of acute renal failure in children. Pediatric Nephrology. 21(12). 1873–1878. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Estelle Verburgh Breakdown of academic impact, for papers by Naoko Hosono Breakdown of academic impact, for papers by Michele Cedrone Breakdown of academic impact, for papers by Vilasini Shetty Breakdown of academic impact, for papers by A. Kuendgen Breakdown of academic impact, for papers by Silvana Capalbo Breakdown of academic impact, for papers by Ryan J. Mattison Breakdown of academic impact, for papers by Arjan van de Loosdrecht Breakdown of academic impact, for papers by Saman Abbas Breakdown of academic impact, for papers by Kathrin Nachtkamp
Rankless by CCL
2026